Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

BACKGROUND: In the PRISMS study, interferon beta-1a subcutaneously (IFN β-1a SC) reduced clinical and radiological disease burden at 2 years in patients with relapsing–remitting multiple sclerosis. The study aimed to characterize efficacy of IFN β-1a SC 44 μg and 22 μg three times weekly (tiw) at Ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Traboulsee, Anthony, Li, David K. B., Cascione, Mark, Fang, Juanzhi, Dangond, Fernando, Miller, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137887/
https://www.ncbi.nlm.nih.gov/pubmed/30217172
http://dx.doi.org/10.1186/s12883-018-1145-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137887/
https://www.ncbi.nlm.nih.gov/pubmed/30217172
http://dx.doi.org/10.1186/s12883-018-1145-x

Ejemplares similares